Background Genome-wide association studies have discovered multiple genetic loci associated with breast cancer risk. Investigating these loci would be helpful to evaluate previous findings and identify causal variants for breast cancer. We evaluated index SNPs in 17 of these loci in a study of 1,511 cases and 1,454 controls of European descent. Methods We investigated the overall association with breast cancer and among subtypes defined as ER? (estrogen receptor positive), ER-(estrogen receptor negative) and triple-negative breast cancer (TNBC). Combined effects of SNPs on breast cancer risk were assessed via a genetic risk score. We evaluated the contribution of both genetic variants and traditional risk factors to a breast cancer risk assessment model. Results Five of the 17 SNPs were significantly associated (P B 0.05) with overall breast cancer in the same direction as previously reported: rs13387042 (2q35/TNP1), rs4973768 (3p24/SLC4A7), rs2046210 (6q25/ESR1), rs1219648 (10q26/FGFR2), and rs4784227 (16q12/TOX3). When stratified by breast cancer subtype, all five SNPs were associated (P \ 0.05) with ER? cancer, three with ER-cancer (rs13387042, rs1219648, and rs4784227), and one with TNBC (rs1219648). A GRS, based on those five significant SNPs, showed strong association with overall breast cancer with ORs (95 % CI) of 1.48 (1.22-1.79), 1.85
Introduction
Breast cancer is one of the most common malignancies, ranking first in incidence and second in mortality for all cancers diagnosed among women in the United States. During 2012, approximately 229,060 women were diagnosed with breast cancer and 39,510 died from this disease in the United States (http://seer.cancer.gov/statfacts/html/ breast.html). Breast cancer is a complex disease in which genetic factors play an important role [1, 2] . To date, four high-penetrance genes (BRCA1, BRCA2, TP53, and PTEN) and four moderate-penetrance genes (CHEK2, ATM, BRIP1, and PALB2) have been discovered for breast cancer [3] . Approximately 70 genetic susceptibility loci have been discovered for breast cancer risk through genome-wide association study (GWAS) [4] [5] [6] [7] [8] [9] [10] .
Breast cancer is a heterogeneous disease. Estrogen receptor (ER), progesterone receptor (PR) and human epidermal growth factor receptor 2 (HER2) are the most commonly used biomarkers for breast cancer subtyping. Women with ER negative (ER-) breast cancer, especially those with triple-negative breast cancer (TNBC) characterized by tumors lacking expression of ER, PR or HER2, have more limited treatment options. With the availability of high-throughput genetic data, it is becoming increasingly apparent that genetic susceptibility to breast cancer varies by tumor subtype. Therefore, it is imperative to evaluate the associations between susceptibility loci and breast cancer by tumor subtypes.
Each of the genetic variants identified in GWAS has only a modest effect in increasing the risk of breast cancer (per allele OR \ 1.3). However, these variants combined may have a more substantial effect. Furthermore, the combination of such genetic factors with traditional risk factors may provide better risk prediction for breast cancer.
In the present study, we investigated risk variants in 17 independent genetic loci previously discovered through GWAS, among participants in the Nashville Breast Health Study (NBHS), a large population-based case-control study. We assessed associations, for single variants and in combination via a genetic risk score, with breast cancer overall and by tumor subtypes. Lastly, we evaluated the contribution of both genetic variants and traditional risk factors to a breast cancer risk assessment model with the goal of better identifying women at higher risk for breast cancer.
Methods

Samples
The Nashville Breast Health Study (NBHS) is a case-control study of breast cancer conducted in the Nashville metropolitan area. Through a rapid case ascertainment system, we identified newly diagnosed breast cancer cases through the Tennessee State Cancer Registry and five major hospitals in the city that provide medical care for breast cancer patients. Eligible cases were women diagnosed between February 1, 2001 and December 31, 2008 with invasive breast cancer and ductal carcinoma in situ (DCIS), who were between the ages of 25 and 75, had no prior history of cancer other than nonmelanoma skin cancer, had a residential telephone, spoke English, and were able to provide consent to the study. Information on ER, PR, and HER2 status of breast tumors was obtained from pathology records. Controls were identified primarily via random digit dialing (RDD) of households in the same geographic area as cases. Eligibility criteria for controls were the same as cases with the exception that controls did not have a prior cancer diagnosis other than simple skin cancer. Controls were frequency matched to cases on 5-year age group, race, and county of residence. Information on demographic factors, as well as known and suspected risk factors for breast cancer, was ascertained through a structured questionnaire administered via telephone interview. Included in the current project are 1,511 cases and 1,454 controls of European ancestry who participated in the study before August 2008 and have donated a buccal cell sample to the study. Buccal cell samples were collected via one of the two methods: Oragene saliva collection kits (DNA GenoteK, Ottawa, Canada) or mouthwash samples. Approval for this study was obtained from the institutional review boards of Vanderbilt University Medical Center and the other participating institutions. All participants provided informed consent prior to enrollment in this study.
Genotyping and sample quality control Genotyping was conducted using the Illumina HumanExome-12v1_A Beadchip which contains 247 k SNPs (http:// genome.sph.umich.edu/wiki/Exome_Chip_Design). Only the GWAS identified variants that were reported in the NHGRI list by August 16, 2011 (http://www.genome.gov/ gwastudies/), i.e., 17 GWAS loci for breast cancer, were included in the chip. Thus, 19 SNPs from the 17 GWAS loci were evaluated in the current study.
All samples were genotyped at the Genome Quebec Innovation Centre (Montreal, Quebec, Canada) following Illumina's protocol. On each 96-well plate, blind duplicate samples and two HapMap samples were included as quality control (QC). Genotype calling was carried out using Illumina's GenTrain version 2.0 clustering algorithm in GenomeStudio version 2011.1. Cluster boundaries were determined using study samples. The samples were excluded if: (1) consistency rates among duplicated samples were less than 99 %, (2) consistency rates between the HapMap samples with 1,000 Genomes Project data were \99 %, (3) an heterozygosity rate outlier, (4) an ethnic outlier, (5) samples indicated close genetic relationship, or (6) samples suggested wrong gender. The SNPs were excluded if: (1) MAF = 0, (2) call rate\98 %, (3) genotyping concordance rate \98 % in QC samples, (4) HWE test P \ 10 -5 , (5) redundant SNPs, or (6) questionable SNPs discovered by the Exomechip Design Group (http://genome.sph.umich.edu/ wiki/Exome_Chip_Design#Cautious_Sites). After these exclusions were applied, 19 SNPs in 17 breast cancer GWAS loci were included in the final dataset. Strong LD (r 2 [ 0.8) was observed between rs2981582 and rs1219648, rs3803662 and rs4784227; therefore, only one SNP in each of these two loci, rs1219648 and rs4784227, respectively, was included in the final analyses.
Statistical analysis
Differences between cases and controls were compared using a Wilcoxon rank-sum test (continuous variables) or v 2 test (categorical variables). Association analysis between each SNP and breast cancer risk was assessed using odds ratios (ORs) and 95 % confidence intervals (CIs) derived from logistic regression models. To evaluate the combined effect of SNPs on breast cancer risk, we created a weighted genetic risk score (GRS) for each study participant by multiplying the number of risk alleles (0/1/2) of each SNP by the weight (log scale of the per-allele OR derived from the current study) for that SNP, and then summing them together. Persons with missing data for a SNP were assigned the average number of risk alleles at that SNP for cases and controls separately. We carried out principal components analysis (PCA) using EIGENSTRAT (http://genepath.med.harvard.edu/*reich/EIGENSTRAT. htm) based on the 3,200 ancestry informative markers (AIMs) on the Exomechip (ftp://share.sph.umich.edu/exo meChip/IlluminaDesigns/AIM/). All analyses were adjusted for age and the top five principal components (PCs). Analyses were also stratified by tumor subtype.
Logistic regression was used to examine independent associations of breast cancer risk for non-genetic factors, including GRS, age at menarche, age at first live birth, parity, body mass index, breast cancer family history, and previous diagnosis of benign breast disease. Factors independently associated with breast cancer risk were used to construct a risk assessment model. The c (or concordance) statistic (i.e., the area under the receiver operating characteristic curve) was used to assess the discriminatory accuracy of the model. A c statistic of 0.5 corresponds to random classification of women with breast cancer and women without breast cancer, whereas perfect classification provides a c statistic of 1.0. The added predictive value of each factor was evaluated by comparing models with and without that predictor with regard to their c statistic [11] . Non-parametric Mann-Whitney U test was used to test the difference in the c statistics between two models [11] . All statistical analyses were conducted in SAS, version 9.3, with the use of two-tailed tests, and R statistical language (http://www.r-project.org/).
Results
Descriptive characteristics for study participants are presented in Table 1 . Five established breast cancer risk factors (age, menopausal status, parity, breast cancer family history, and previous benign breast disease diagnosis) differed significantly between breast cancer patients and controls (P B 0.05).
For overall breast cancer risk, SNPs at five loci, including 2q35/TNP1, 3p24/SLC4A7, 6q25/ESR1, 10q26/ FGFR2, and 16q12/TOX3 were associated (P B 0.05) in the same direction as previously reported (Table 2) , with the rs1219648 located in 10q26/FGFR2 being the strongest predictor. Adjusted odds ratios (95 % CI) were 1.56 (1.33-1.84) and 1.75 (1.41-2.17), respectively, for genotypes A/G and G/G versus A/A for the SNP rs1219648 (P for trend 1.4 9 10 -8 ). Allelic ORs (95 % CI) for the other four SNPs were 1.22 (1.10-1.35) for rs13387042 (P = 2.0 9 10 -4 ), 1.14 (1.03-1.26) for rs4973768 (P = 0.02), 1.14 (1.02-1.27) for rs2046210 (P = 0.02), and 1.26 (1.12-1.42) for rs4784227 (P = 9.7 9 10 -5
). No significant associations were observed for the other 12 SNPs, however, ORs for 10 of the SNPs were in similar directions as previous reports. The associations between SNPs and breast cancer subtypes are presented in Table 3 . Among the five SNPs that were associated with overall breast cancer, all of them were significantly associated (P \ 0.05) with ER? cancer, three with ER-cancer (rs13387042, rs1219648, and rs4784227), and one with TNBC (rs1219648). SNP rs11249433 at 1p11/FCGR1B and rs2380205 at 10p15/ ANKRD16 were associated with ER-breast cancer with ORs (95 % CI) of 1.18 (0.98-1.41) (P = 0.07) and 1.19 (0.99-1.42) (P = 0.06), respectively. SNP rs1045485 at 2q33/CASP8 was associated with TNBC with an OR (95 % CI) of 1.55 (1.02-2.34) (P = 0.04).
GRS analyses based on five significant SNPs showed significant associations with breast cancer, overall and by subtype ( Table 4 ). The ORs (95 % CIs) for overall breast cancer risk across increasing quartiles of GRS were 1.48 (1.22-1.79), 1.85 (1.52-2.25) and 2.26 (1.82-2.80), respectively, (P = 2.0 9 10 -15 ) compared to the lowest quartile. Similar associations also were observed when stratified by breast cancer subtypes, menopausal status, age of onset, or breast cancer family history (Table 4) . GRS genetic risk score a GRS (genetic risk score) was constructed based on five SNPs, including rs13387042, rs4973768, rs2046210, rs1219648, and rs4784227
Logistic regression analyses showed that GRS (based on its quartile distribution in the control subjects), parity, breast cancer family history, and previous diagnosis of benign breast disease were independently associated with breast cancer risk (Table 5 ). These factors were used to construct a risk assessment model. The contribution of these risk factors to the risk assessment model is presented in Table 6 . The c statistic for the full model was 0.6321. The contribution of the GRS to the model, as measured by the reduction in adjusted c statistic from the full model, was 0.0374. Notably, the effect of GRS was stronger than breast cancer family history (reduction in adjusted c statistic = 0.0103), and prior benign breast disease (reduction in adjusted c statistic = 0.0324) with a statistically significant P value (P B 0.05). We did not evaluate age at menarche, age at first live birth, and body mass index in the risk assessment model since these factors were not significantly associated with the risk of breast cancer in our study (data not shown).
Discussion
In the current study, we investigated associations between index SNPs in 17 breast cancer susceptibility loci and incident breast cancer in 1,511 cases and 1,454 controls from European-ancestry women. As expected, each SNP identified in GWAS was associated with a small to moderate increased risk of breast cancer. We found that five SNPs at 2q35/TNP1, 3p24/SLC4A7, 6q25/ESR1, 10q26/ FGFR2, and 16q12/TOX3 loci were significantly associated (P B 0.05) with overall breast cancer risk in the same direction as previously reported. GRS analyses, based on those five significant SNPs, showed significant associations with overall breast cancer and breast cancer stratified by subtype, menopausal status, age of onset or breast cancer family history. GRS and previous benign breast disease are the two top predictors in the risk assessment model.
Among the five loci that are significantly associated with breast cancer risk in our study population, all of them showed nominally significant associations with ER? cancer, and three of them with ER-cancer (rs13387042, rs1219648, and rs4784227). The strength of association was stronger for ER? than ER-cancer, which is consistent with previous studies [4, 9, 12, 13] . In addition, for the other two SNPs, rs11249433 at 1p11/FCGR1B and rs2380205 at 10p15/ANKRD16, a suggestive association with ER-, but not ER? cancer was observed. Recently, two SNPs (rs2046210 at 6q25/ESR1 and rs8170 at 19p13/ BABAM1) were found to be associated with ER-cancer [12] . In the present study, only a suggestive association was observed at SNP rs2046210 and no association was found for rs8170 with ER-cancer.
In the present study, two SNPs, including rs1045485 (2q33/CASP8) and rs1219648 (10q26/FGFR2) were associated with TNBC. Similarly, rs1045485 showed a stronger association with ER-than ER? in the Breast Cancer Association Consortium (BCAC) [14] . However, the association of rs1219648 with TNBC was not replicated in the BCAC [14] nor the Triple Negative Breast Cancer Consortium (TNBCC) [15] . In the TNBCC [15] , 6q25/ ESR1, 16q12/TOX3, 14q24/RAD51L1, and 19p13/BA-BAM1 were significantly associated with the risk of TNBC. However, only two of them, 19p13/BABAM1 and 16q12/ TOX3, were replicated in the BCAC [14, 16] . In the present study, a similar, but non-significant association was In the present study, we were only able to replicate the association between five of the 17 loci in association with overall breast cancer risk. Small sample size is likely to be the major reason for the non-replication. Most of the GWAS-identified loci were associated with small effect size, which resulted in limited statistical power for replication in studies with a sample size like the present study. Notably the statistical power was limited for the breast cancer subtype analysis. Another limitation of the present study is that although approximately 67 GWAS loci have already been reported in the literature, only 17 of them were investigated in the present study. In the present study, the Exomechip was used as our genotyping platform. This chip was designed by a large consortium from multiple institutes based on sequencing data from over 12,000 subjects (http://genome.sph.umich.edu/wiki/ Exome_Chip_Design). All variants added to GWAS catalog by August 16, 2011 were included in the chip; however, variants identified after that time were not included. We will plan to investigate those identified loci after August 16, 2011 in future studies. Despite this, the GRS, the combination of five loci, was one of the strongest predictors in our risk assessment model. This suggests that in addition to the traditional risk factors, genetic variants are important in risk assessment. The full risk assessment model established in this study provided only moderate discriminatory accuracy with a c statistic of 0.6321, however, there is advantage in including genetic variants since they can be accurately measured at any time during a person's entire life. Including all 67 GWAS loci in the model should further improve the prediction accuracy and may serve as a useful tool for identifying high-risk women for close monitoring and cancer screening.
Conclusion
In summary, we have evaluated index SNPs in 17 breast cancer susceptibility loci that were initially identified by GWAS studies for their association with breast cancer in the NBHS. Five of them were associated with overall breast cancer. Two SNPs were nominally significantly associated with TNBC. The GRS is one of the strongest predictors of breast cancer risk in our risk assessment model, suggesting the potential utility of using GRS in identifying women who are at high risk of breast cancer.
